# A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct02548585` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02548585](<https://clinicaltrials.gov/study/NCT02548585>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02548585

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 113 participants.

## Technical summary

Registry record NCT02548585. Randomized; quadruple masking; primary purpose treatment. Start 2015-12-09 (actual); primary completion 2017-02-24 (actual). Results posted on 2019-04-05.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 1/2
- Enrolled: 113 participants (enrolled count; ClinicalTrials.gov record NCT02548585, source copy `cardio:ctgov-nct02548585-2019-04-05`, retrieved 2026-10-26)
- Started: 2015-12-09 (actual) (ClinicalTrials.gov record NCT02548585, source copy `cardio:ctgov-nct02548585-2019-04-05`, retrieved 2026-10-26)
- Primary completion: 2017-02-24 (actual) (ClinicalTrials.gov record NCT02548585, source copy `cardio:ctgov-nct02548585-2019-04-05`, retrieved 2026-10-26)
- Completion: 2017-02-24 (actual) (ClinicalTrials.gov record NCT02548585, source copy `cardio:ctgov-nct02548585-2019-04-05`, retrieved 2026-10-26)
- Results first posted: 2019-04-05 (ClinicalTrials.gov record NCT02548585, source copy `cardio:ctgov-nct02548585-2019-04-05`, retrieved 2026-10-26)
- Countries: Germany (ClinicalTrials.gov record NCT02548585, source copy `cardio:ctgov-nct02548585-2019-04-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02548585-2019-04-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): MEDI0382
- Intervention (Drug): Placebo
- Lead sponsor: MedImmune LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: MedImmune LLC (`cardio:org-medimmune-llc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study (`cardio:pubmed-29945727`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Characterisation of cotadutide's dual GLP-1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model (`cardio:pubmed-38403793`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 4f2ad36e24d839a00d322f4240906409e873dc527e3b207d8eedc75dbb9d2ac8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
